MIAMI / Apr 30, 2025 / Business Wire / Ontrak, Inc. (NASDAQ: OTRK), a leading value-based behavioral healthcare company powered by proprietary AI and engagement technology, announced it has been re-certified by the National Committee for Quality Assurance (NCQA) as a Credentials Verification Organization (CVO) for the element of license to practice. This re-certification reaffirms Ontrak’s ongoing commitment to maintaining the highest standards of quality and compliance across its suite of healthcare solutions, helping health plan customers effectively meet their accreditation goals.
NCQA, a recognized leader in healthcare quality assessment, evaluation, and certification, grants this prestigious re-certification after a voluntary review process and evaluation of a CVO’s management of various aspects of its data collection and verification operation, and the process it uses to continuously improve the services it provides.
“This re-certification is more than a compliance milestone, it’s a reflection of our unwavering commitment to trust, transparency, and operational excellence.” said Brandon LaVerne, Chief Executive Officer and Chief Operating Officer at Ontrak. “At Ontrak health, we anchor our identity around the impact we deliver, and this recognition reinforces the confidence our partners, members, and health plan customers place in us every day.”
“Achieving CVO certification from NCQA demonstrates that Ontrak Health has the systems, process and personnel in place to thoroughly and accurately verify providers' credentials and help health plan clients meet their accreditation goals,” commented Margaret E. O’Kane, President of the NCQA.
Ontrak’s renewed NCQA certification will extend through April 22, 2027.
About Ontrak, Inc.
Ontrak Health (Nasdaq: OTRK) is a leading value-based behavioral healthcare company powered by proprietary AI and engagement technology, whose mission is to help improve the health and save the lives of as many people as possible. Ontrak uniquely identifies, engages, and delivers care to the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. Through our Advanced Engagement System, we achieve higher engagement rates with individuals with anxiety, depression, substance use disorder and chronic disease by delivering personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socio-economic, medical and health system barriers that exacerbate the severity of their comorbid illnesses. The company’s whole-person approach integrates AI, predictive analytics, comprehensive clinical and claims data, patient-generated information, and digital interfaces with care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.
About NCQA
NCQA is a private, nonprofit organization dedicated to improving health care quality. NCQA accredits and certifies a wide range of health care organizations. It also recognizes clinicians and practices in key areas of performance. NCQA’s Healthcare Effectiveness Data and Information Set (HEDIS®) is the most widely used performance measurement tool in health care. NCQA’s website (ncqa.org) contains information to help consumers, employers and others make more informed health care choices. NCQA can be found online at ncqa.org, on Twitter @ncqa, on Facebook at facebook.com/NCQA.org/ and on LinkedIn at linkedin.com/company/ncqa.
Learn more at www.ontrakhealth.com.
Last Trade: | US$1.57 |
Daily Volume: | 14,352 |
Market Cap: | US$6.630M |
February 19, 2025 November 13, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load